These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 7083730)

  • 1. Central hemodynamic effects of dipyridamole in severe heart failure: comparison with hydralazine.
    Packer M; Gorlin R; Meller J; Medina N
    Clin Pharmacol Ther; 1982 Jul; 32(1):54-61. PubMed ID: 7083730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sustained hemodynamic response to flosequinan in patients with heart failure receiving angiotensin-converting enzyme inhibitors.
    Gottlieb SS; Kukin ML; Penn J; Fisher ML; Cines M; Medina N; Yushak M; Taylor M; Packer M
    J Am Coll Cardiol; 1993 Oct; 22(4):963-7. PubMed ID: 8409070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hemodynamic characterization of tolerance to long-term hydralazine therapy in severe chronic heart failure.
    Packer M; Meller J; Medina N; Yushak M; Gorlin R
    N Engl J Med; 1982 Jan; 306(2):57-62. PubMed ID: 7053487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of short-term oral hydralazine therapy on exercise hemodynamics in patients with severe chronic heart failure.
    Rubin SA; Chatterjee K; Ports TA; Gelberg HJ; Brundage BH; Parmley WW
    Am J Cardiol; 1979 Nov; 44(6):1183-9. PubMed ID: 495513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Results of long-term vasodilator therapy in patients with refractory congestive heart failure.
    Walsh WF; Greenberg BH
    Circulation; 1981 Sep; 64(3):499-505. PubMed ID: 7261282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral hydralazine therapy for chronic refractory heart failure.
    Chatterjee K; Parmley WW; Massie B; Greenberg B; Werner J; Klausner S; Norman A
    Circulation; 1976 Dec; 54(6):879-83. PubMed ID: 825327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differences in hemodynamic response to vasodilation due to calcium channel antagonism with nifedipine and direct-acting agonism with hydralazine in chronic refractory congestive heart failure.
    Elkayam U; Weber L; McKay CR; Rahimtoola SH
    Am J Cardiol; 1984 Jul; 54(1):126-31. PubMed ID: 6741802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vasodilators as first-line therapy for congestive heart failure: a comparative hemodynamic study of hydralazine, digoxin, and their combination.
    Ribner HS; Zucker MJ; Stasior C; Talentowski D; Stadnicki R; Lesch M
    Am Heart J; 1987 Jul; 114(1 Pt 1):91-6. PubMed ID: 3604877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hydralazine pharmacodynamics in the dog.
    Kittleson MD; Hamlin RL
    Am J Vet Res; 1983 Aug; 44(8):1501-5. PubMed ID: 6625299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Provocation of myocardial ischemic events during initiation of vasodilator therapy for severe chronic heart failure. Clinical and hemodynamic evaluation of 52 consecutive patients with ischemic cardiomyopathy.
    Packer M; Meller J; Medina N; Yushak M; Gorlin R
    Am J Cardiol; 1981 Nov; 48(5):939-46. PubMed ID: 7304442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of tolerance to hemodynamic effects of nitrates with concomitant use of hydralazine in patients with chronic heart failure.
    Gogia H; Mehra A; Parikh S; Raman M; Ajit-Uppal J; Johnson JV; Elkayam U
    J Am Coll Cardiol; 1995 Dec; 26(7):1575-80. PubMed ID: 7594088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral hydralazine in chronic heart failure: sustained beneficial hemodynamic effects.
    Chatterjee K; Ports TA; Brundage BH; Massie B; Holly AN; Parmley WW
    Ann Intern Med; 1980 May; 92(5):600-4. PubMed ID: 7386999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Hemodynamic effects of hydralazine in the cardiac insufficiency of non-obstructive myocardiopathy].
    Pailloncy M; Fernandez F; Lelguen C; Datchary J; Ponsonnaille J; Gerbaux A; Gras H
    Arch Mal Coeur Vaiss; 1979 Mar; 72(3):276-83. PubMed ID: 114138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short- and long-term effects of hydralazine and combined hydralazine-prenalterol therapy in severe chronic congestive heart failure.
    Drexler H; Löllgen H; Just H
    Klin Wochenschr; 1981 Jun; 59(12):647-54. PubMed ID: 7253539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hemodynamic evaluation of hydralazine dosage in refractory heart failure.
    Packer M; Meller J; Medina N; Gorlin R; Herman MV
    Clin Pharmacol Ther; 1980 Mar; 27(3):337-46. PubMed ID: 7357790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hemodynamic effects of BTS 49465, a new long-acting systemic vasodilator drug, in patients with severe congestive heart failure.
    Kessler PD; Packer M
    Am Heart J; 1987 Jan; 113(1):137-43. PubMed ID: 3799427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamic responses to continuous use of prazosin and hydralazine in patients with refractory heart failure.
    Elkayam U; Mathur M; Frishman W; LeJemtel T; Strom J; Sonnenblick EH
    Clin Pharmacol Ther; 1981 Jul; 30(1):23-30. PubMed ID: 7237894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hemodynamic effects of hydralazine in infants with idiopathic dilated cardiomyopathy and congestive heart failure.
    Artman M; Parrish MD; Appleton S; Boucek RJ; Graham TP
    Am Heart J; 1987 Jan; 113(1):144-50. PubMed ID: 3799428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative hemodynamic effects of mexiletine and quinidine in patients with severe left ventricular dysfunction.
    Gottlieb SS; Weinberg M
    Am Heart J; 1991 Nov; 122(5):1368-74. PubMed ID: 1951002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hemodynamic effects of hydralazine in infants with a large ventricular septal defect.
    Beekman RH; Rocchini AP; Rosenthal A
    Circulation; 1982 Mar; 65(3):523-8. PubMed ID: 6459891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.